Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Long-Term Debt Repayments (2024 - 2025)

Rani Therapeutics Holdings has reported Long-Term Debt Repayments over the past 2 years, most recently at $9.5 million for Q4 2025.

  • Quarterly results put Long-Term Debt Repayments at $9.5 million for Q4 2025, up 152.59% from a year ago — trailing twelve months through Dec 2025 was $20.7 million (up 314.44% YoY), and the annual figure for FY2025 was $20.7 million, up 314.44%.
  • Long-Term Debt Repayments for Q4 2025 was $9.5 million at Rani Therapeutics Holdings, up from $3.8 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for RANI hit a ceiling of $9.5 million in Q4 2025 and a floor of $1.2 million in Q3 2024.